Core Evidence evaluates the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to postlaunch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups
The emerging evidence on new drugs is reviewed at key stages of development and evaluated against unmet needs
Review
Phase
Focus
Emerging therapy
Preclinical and phase I
Unmet medical needs and outcomes required to demonstrate clinical value
Proof of concept
Phase II
What is the clinical potential?
Outcomes
Phase III
What is the preliminary place in therapy based on emerging evidence?
Place in therapy
Launch
Evidence supporting place in therapy in approved indications
